戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 evelopment of 2 as a novel second-generation antipsychotic agent.
2  variant was applied to rodents receiving an antipsychotic agent.
3 uperior therapeutic effects of this atypical antipsychotic agent.
4 several of the criteria for a novel atypical antipsychotic agent.
5 se I clinical trials as a potential atypical antipsychotic agent.
6 estigated as an approach to a novel atypical antipsychotic agent.
7 mplications for understanding the actions of antipsychotic agents.
8 st-generation and several recently-developed antipsychotic agents.
9 , indicating their potential as nonclassical antipsychotic agents.
10 rom monitoring should guide the selection of antipsychotic agents.
11 ffect of race on the use of various atypical antipsychotic agents.
12 nd release and may have potential utility as antipsychotic agents.
13 prepared and evaluated as potential atypical antipsychotic agents.
14  occupancy of striatal dopamine receptors by antipsychotic agents.
15 isdiagnosis and inappropriate treatment with antipsychotic agents.
16 1), were prepared and evaluated as potential antipsychotic agents.
17 cy of four novel, evidence-based targets for antipsychotic agents: a neurokinin (NK(3)) antagonist (S
18 tion may be useful for testing potential new antipsychotic agents and for characterizing neurobiologi
19 er between psychiatric subjects treated with antipsychotic agents and normal controls.
20            In light of the efficacy of newer antipsychotic agents and the possibility that drug withd
21 rugs is associated with clinical response to antipsychotic agents and the production of extrapyramida
22 n the biological activity of these potential antipsychotic agents are discussed.
23 (3) receptors targeted by the most effective antipsychotic agents are maximally expressed, could lead
24 stigated the efficacy of lurasidone, a novel antipsychotic agent, as adjunctive therapy with lithium
25 suggest that in patients with schizophrenia, antipsychotic agents associated with pneumonia include n
26 hanges in response to the advent of atypical antipsychotic agents can be understood in the context of
27 3, that have been evaluated in the clinic as antipsychotic agents (Chart 2).(2)
28 m chloride or systemic administration of the antipsychotic agent clozapine.
29                          Sertindole is a new antipsychotic agent effective for the treatment of both
30                                    The newer antipsychotic agents exhibit a superior safety profile c
31                        Olanzapine is a novel antipsychotic agent exhibiting regional mesolimbic dopam
32 e benefits of the continued use of a typical antipsychotic agent following remission from an acute ma
33 ere 18 to 68 years old, were treated with an antipsychotic agent for 6 months or more at a stable dos
34 panel recommendations regarding choice of an antipsychotic agent for schizophrenia differ markedly, b
35 n criteria were >/=18 years old, were taking antipsychotic agents for >/=30 days, and had a body mass
36 om the trial for lack of efficacy, or use of antipsychotic agents for dementia-related psychosis.
37  receptor affinity comparable to the typical antipsychotic agent haloperidol and a 5-HT2A/D2 ratio co
38                  Patterns of clinical use of antipsychotic agents have changed greatly in the past de
39  2.89; 95% CI, 1.51 to 5.55; P=0.001), or an antipsychotic agent (hazard ratio, 3.02; 95% CI, 1.34 to
40  data on the safety and efficacy of atypical antipsychotic agents in children are limited.
41             Current use of second-generation antipsychotic agents in daily doses of less than or equa
42 cacy and tolerability of adjunctive atypical antipsychotic agents in major depressive disorder.
43 ic drugs, by definition, differ from typical antipsychotic agents in producing significantly fewer ex
44 or safety profile compared with conventional antipsychotic agents in terms of extrapyramidal symptoms
45 ilize omega-3, anticonvulsants, and atypical antipsychotic agents in treating specific DSM-5 BPD trai
46                            However, atypical antipsychotic agents, in combination with the nicotine t
47 therapeutic profile of atypical over typical antipsychotic agents include 1) simultaneous antagonism
48    Notably, the prescription probability for antipsychotic agents increased 249% during the study epo
49                                        Novel antipsychotic agents introduce new pharmacological avenu
50         This model for identifying potential antipsychotic agents is based on the hypothesis that age
51  schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypica
52  muscle, suggesting that this older class of antipsychotic agents may have utility in being repurpose
53  injectable risperidone, a second-generation antipsychotic agent, may improve adherence to treatment
54 antipsychotic-induced constipation indicates antipsychotic agents might affect gastrointestinal motil
55 to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conven
56                   Ten C57-B mice received an antipsychotic agent or vehicle control.
57 uation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to tha
58     Moreover, we identified that the typical antipsychotic agent pimozide is a SCOT inhibitor that ca
59 nuous infusion to examine the effects of the antipsychotic agent RWJ-37796, on striatal activity in h
60 modern psychotropic agents, such as atypical antipsychotic agents, selective serotonin reuptake inhib
61 is response is specific to second-generation antipsychotic agents (SGAs), as first-generation medicat
62             At their clinical doses, current antipsychotic agents share the property of both dopamine
63         The study results suggest that novel antipsychotic agents such as olanzapine should be consid
64                                              Antipsychotic agents, such as quetiapine, aripiprazole,
65 ned with an anxiolytic, mood stabilising, or antipsychotic agent), supportive psychotherapy (often co
66 cinations in schizophrenia are alleviated by antipsychotic agents that inhibit D2 dopamine receptors
67 e 2 diabetes associated with use of selected antipsychotic agents, the authors conducted a new-user c
68     To report the use of a second-generation antipsychotic agent to assist weaning from prolonged mec
69 ferences in mortality risks among individual antipsychotic agents used for treating patients with dem
70                   EEG abnormality risk among antipsychotic agents varied greatly (clozapine=47.1%, ol
71 on of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (clozapine)
72                               This potential antipsychotic agent was not developed further due to und
73                          A second-generation antipsychotic agent was successfully used to facilitate
74 t and imaging studies in mice suggested that antipsychotic agents were not confounding the primary fi
75     A number of dopamine receptor antagonist/antipsychotic agents were shown to block hKv2.1.
76                                     Atypical antipsychotic agents, which block postsynaptic dopamine
77                      Further work with other antipsychotic agents will be necessary to determine if i
78                    Quetiapine is an atypical antipsychotic agent with a complex pharmacology, includi
79 sses activity consistent with an efficacious antipsychotic agent with less tendency to induce extrapy
80 tial agonists such as 14 may have utility as antipsychotic agents with increased efficacy and decreas
81 ogues (4a,b and 9a, b) to be the most potent antipsychotic agents with large separation between effic
82                    Manufacturers of atypical antipsychotic agents without online registries were cont